PL1786790T3 - Pochodne oksazolu jako środki receptora histaminowego H3, ich wytwarzanie i terapeutyczne zastosowanie - Google Patents

Pochodne oksazolu jako środki receptora histaminowego H3, ich wytwarzanie i terapeutyczne zastosowanie

Info

Publication number
PL1786790T3
PL1786790T3 PL05773290T PL05773290T PL1786790T3 PL 1786790 T3 PL1786790 T3 PL 1786790T3 PL 05773290 T PL05773290 T PL 05773290T PL 05773290 T PL05773290 T PL 05773290T PL 1786790 T3 PL1786790 T3 PL 1786790T3
Authority
PL
Poland
Prior art keywords
histamine
nitrogen
formula
ring
compounds
Prior art date
Application number
PL05773290T
Other languages
English (en)
Inventor
Lisa Selsam Beavers
Serge Louis Boulet
Terry Patrick Finn
Robert Alan Gadski
William Joseph Hornback
Cynthia Darshini Jesudason
Richard Todd Pickard
Freddie Craig Stevens
Grant Matthews Vaught
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1786790T3 publication Critical patent/PL1786790T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL05773290T 2004-07-26 2005-07-14 Pochodne oksazolu jako środki receptora histaminowego H3, ich wytwarzanie i terapeutyczne zastosowanie PL1786790T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59119104P 2004-07-26 2004-07-26
EP05773290A EP1786790B1 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
PCT/US2005/024883 WO2006019833A1 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
PL1786790T3 true PL1786790T3 (pl) 2009-10-30

Family

ID=35134220

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05773290T PL1786790T3 (pl) 2004-07-26 2005-07-14 Pochodne oksazolu jako środki receptora histaminowego H3, ich wytwarzanie i terapeutyczne zastosowanie

Country Status (17)

Country Link
US (1) US7666871B2 (pl)
EP (1) EP1786790B1 (pl)
JP (1) JP4982367B2 (pl)
CN (1) CN1989115B (pl)
AT (1) ATE432926T1 (pl)
AU (1) AU2005275183B2 (pl)
BR (1) BRPI0513777A (pl)
CA (1) CA2575081C (pl)
CY (1) CY1109493T1 (pl)
DE (1) DE602005014786D1 (pl)
DK (1) DK1786790T3 (pl)
ES (1) ES2325865T3 (pl)
MX (1) MX2007001029A (pl)
PL (1) PL1786790T3 (pl)
PT (1) PT1786790E (pl)
SI (1) SI1786790T1 (pl)
WO (1) WO2006019833A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
US7728009B1 (en) 2005-02-18 2010-06-01 Neurogen Corporation Thiazole amides, imidazole amides and related analogues
EP1866293A1 (en) * 2005-03-31 2007-12-19 UCB Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
RU2418793C2 (ru) 2005-11-15 2011-05-20 Оцука Фармасьютикал Ко., Лтд. Соединение оксазола и фармацевтическая композиция
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
CA2649913A1 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
US20090215628A1 (en) * 2006-05-19 2009-08-27 Basf Se Benzoyl-Substituted Alanines
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
US7803825B2 (en) 2007-07-16 2010-09-28 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
WO2009126782A1 (en) * 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US8383829B2 (en) * 2008-04-15 2013-02-26 Konica Minolta Holdings, Inc. Electrochromic compound, electrode, and display element
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
ES2527466T3 (es) 2010-07-06 2015-01-26 Astrazeneca Ab Agentes terapéuticos 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2948447B1 (en) 2013-01-23 2016-09-21 Astrazeneca AB Chemical compounds
EP3233828B1 (en) * 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Estrogen receptor modulators and uses thereof
PH12017502158B1 (en) 2015-06-03 2022-04-27 Bristol Meyers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
CA3049443A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
WO1995009159A1 (en) * 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Quinoxaline derivative as antidiabetic agent
AU3957600A (en) 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
WO2002076925A2 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
PL371435A1 (pl) 2002-02-01 2005-06-13 Novo Nordisk A/S Amidy aminoalkilo-podstawionych azetydyn, pirolidyn, piperydyn i azepanów
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents

Also Published As

Publication number Publication date
BRPI0513777A (pt) 2008-05-13
WO2006019833A1 (en) 2006-02-23
DE602005014786D1 (de) 2009-07-16
JP2008507579A (ja) 2008-03-13
PT1786790E (pt) 2009-08-18
EP1786790B1 (en) 2009-06-03
US7666871B2 (en) 2010-02-23
CN1989115B (zh) 2012-03-21
SI1786790T1 (sl) 2009-10-31
MX2007001029A (es) 2007-04-12
CA2575081C (en) 2013-05-07
DK1786790T3 (da) 2009-07-20
CN1989115A (zh) 2007-06-27
AU2005275183B2 (en) 2011-03-17
AU2005275183A1 (en) 2006-02-23
ATE432926T1 (de) 2009-06-15
US20070197604A1 (en) 2007-08-23
JP4982367B2 (ja) 2012-07-25
ES2325865T3 (es) 2009-09-22
EP1786790A1 (en) 2007-05-23
CY1109493T1 (el) 2014-08-13
CA2575081A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
CY1109493T1 (el) Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
NZ588121A (en) Novel estrogen receptor ligands
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
MY142807A (en) Benzimidazole derivative and use thereof.
TW200716528A (en) Cyclopropanecarboxamide derivatives
NZ548196A (en) Aryl aniline derivatives as beta2 adrenergic receptor agonists
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
GB0701366D0 (en) Novel pharmaceutical compositions
MX2009007914A (es) Composiciones farmaceuticas novedosas.
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
PT1828177E (pt) Novos antagonistas dos receptores da mch
MX2007005709A (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos.
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
TW200531694A (en) Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
JP2010513489A5 (pl)
TW200621223A (en) Acyclic 1,3-diamines and uses therefor
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung
EA201071259A1 (ru) Спиро(пиперидин-4,2-пирролидин)-1-(3,5-трифторметилфенил)метилкарбоксамиды в качестве антагонистов рецептора nk1 тахикинина
TNSN08093A1 (en) Quinoline derivatives and use as antitumor agents